Key Points Question What is the updated magnitude of benefit associated with sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) on outcome of cardiovascular death or hospitalization for heart failure (HHF) in different… Click to show full abstract
Key Points Question What is the updated magnitude of benefit associated with sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) on outcome of cardiovascular death or hospitalization for heart failure (HHF) in different select subgroups of patients? Findings This meta-analysis of 10 high-quality randomized clinical trials (71 553 participants) found that use of SGLT2-Is was associated with lower occurrence of cardiovascular death or HHF by 33% in high-risk patients. For the primary outcome of HHF or cardiovascular death, the study showed equal benefit of SGLT2-Is in both sexes; lower risk in participants who were younger than 65 years compared with those 65 years or older; and greater risk reduction in participants who were Asian, Black, or of other races or ethnicities compared with White participants. Meaning These findings suggest that SGLT2-Is may be associated with an overall cardiovascular benefit for patients with high-risk cardiovascular features compared with placebo in both sexes, different age groups and different races and ethnicities.
               
Click one of the above tabs to view related content.